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Abstract: An alloantibody to a high-incidence antigen, asso- 
ciated with multiple other alloantibodies, made it impossible to 
supply antigen-negative red blood cells (RBCs) for a chronically 
transfused sickle cell anemiapatient. Anti-Cr sup(a), -E, K, -S, -Fy sup(a), -Fy sup(b), as 
well as anti-M reactive at 37°C and in the antiglobulin phase of test- 
Cr(a -), M + , E - , K - , S - , Fy(a - b -) units. Anti-Cr sup(a) is 
considered to be a clinically significant alloantibody 
The Cr(a-) phenotype is found almost exclusively in 
blacks, with the incidence of Cr(a -) individuals esti- 
ing, were identified in the patient's serum. An extensive search of 
rare donor files at the American Red Cross and at the American AS- 
sociation of Blood Banks (AABB) failed to identify C r(a-),M-,E-, 
K - , S - , Fy(a - b -) donors. Various studies were performed to pre- 
dict the clinical significance of the anti-Cr sup(a) and anti-M. Results of 
sup(51)chromium survival studies showed 91.8 percent survival at 10 
minutes and 87.2 percent survival at 60 minutes with Cr(a +), M - , 
E - , K -  , S - , Fy(a - h -) red cells, suggesting that immediate de- 
struction of transfused CrCa+) red cells would he unlikely How- 
mated at 1 in 5,000 black donors.' Although anti-M of- 
ten is not clinically significant, it should be considered 
of hemolytic potential if the antibody is reactive at 
37°C or in the IAT. sup(2) Various studies were performed to 
predict the clinical significance of the anti-Cr sup(a) and -M 
in this patient. 
Case History 
A blood sample from a 37-year-old black male with 
sickle cell anemia was referred to a reference labora- 
tory for investigation of multiple antibodies. The pa- 
tient had received two units of blood l l months earlier. 
The patient's RBCs were phenotyped as C + c 
+ D + E - e + ,  M - N + ,  S-s+, K - ,  Fy(a-b-), 
Jk(a + b +), Le(a - b +) and the patient's serum con- 
tained anti-M, -S, and -Fy sup(a). Since the anti-M was not de- 
monstrable in saline at 37°C or by the IAT, transfusion 
of M - red cells was not recommended. The patient 
was transfused with three units of S - ,  Fy(a-), 
crossmatch-compatible RBCs. Two weeks later, the he- 
matocrit was 20 percent, and anti-M, -E, -K, -S, -Fy sup(a), -Fy sup(b), 
and a weak unidentified antibody were detected. The 
anti-M was now reactive 4+ at room temperature 
(RT), 37°C, and by the IAT using a prewarmed saline 
technique. The patient's clinical status necessitated 
transfusion of four units of M-, E - ,  K - ,  S-,  
Fy(a - b -), least incompatible RBCs. The hematocrit 
rose initially to 24 percent following transfusion, but 
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dropped to 18 percent within the next two weeks. The 
weakunidentified antibody was identified at Red Cross 
national headquarters reference laboratory as anti-Cr sup(a); 
anti-Lu sup(a) and an autoanti-I were also detected. The pa- 
tient's direct antiglobulin test (DAT) was negative and 
his cells were typed as Cr(a-) with two examples of 
anti-Cr sup(a). No compatible blood was available for transfu- 
sion. When a sample was submitted one month post- 
transfusion, microscopic antiglobulin reactivity was 
still evident with M - , E - , K-, S - , Fy(a- b -) re- 
agent RBCs. 
Following a monocyte monolayer assay (MMA) sug- 
gesting that both anti-Cr sup(a) and -M would be clinically 
significant, the patient was treated with corticoste- 
roids for two months. sup(51)Cr-survival studies were done 
near the end of the treatment period. 
Materials and Methods 
Serologic studies 
Standard serologic methods sup(3) were used for all test- 
ing. Antibody detection and identification were per- 
formed with commercial reagent RBCs in LISS and 
Polybrene media. Ficin capillary techniques were used 
at Red Cross national headquarters to detect the 
anti-Cr sup(a). Red cell typings were performed using com- 
mercial blood grouping reagents according to manu- 
facturer's directions. 
Blood samples drawn at 60 minutes, 24 hours, 6 
days, and 14 days post-injection of sup(51)cr-labeled RBCs 
were tested against the Cr(a +), M - , E - , K -  , S - , 
Fy(a-b-) donor cells in LISS-IAT: A DAT was per- 
formed on each sample using polyspecific antihuman 
globulin, and an eluate (acid elution) was prepared 
when indicated. 
Survival studies 
Red cell survival studies were performed using a 
5-mL aliquot of Cr(a +), M - , E -, K-,  S-, Fy(a- b -) 
donor RBCs labeled with 100 µCi sup(51)chromium. The 
donor cells were phenotypically matched except for 
the Cr sup(a) antigen. Blood samples were collected at 3 
minutes, 10 minutes, 60 minutes, 24 hours, 48 hours, 6 
days, and 14 days following injection of radiolabeled 
RBCs. Radioactivity in the red cell sample collected at 
three minutes was designated as 100 percent for calcu- 
lating the percent of RBC survival. 
Monocyte monolayer assay (MMA) 
A MMA sup(4) was performed to assess the clinical signifi- 
cance of anti-M and -Cr sup(a). Normal donor mononuclear 
cell layers were incubated with Cr(a+), M-  and 
Cr(a -), M + reagent RBCs sensitized with the patient's 
antibodies. Monocyte-RBC interaction was reported as 
percent ofreactive monocytes. Testing was done in du- 
plicate with and without the addition of fresh comple- 
ment and also on serum treated with dithiothreitol 
(DTT) to remove IgM activity The total reactivity was 
measured as % adherence + phagocytosis/200 mono- 
cytes. 
Results  
The results of the monocyte monolayer assay are 
shown in Table 1. The study was performed on a one- 
month posttransfusion sample; anti-Cr sup(a) was micro- 
scopically demonstrable at that time. Those results 
suggested that both the anti-M (18%) and anti-Cr sup(a) 
(5.9%) would be clinically significant and that reactiv- 
ity was enhanced in the presence of complement. 
Table 1. 
MMA results with Cr(a-) ,  M + or M -, E - .  K - ,  S- .  Fyia- b-) 
cells 
Coated test RBCs Reactive 
RBC phenotype 37°C anti-lgG monocytes*% 
Cr(a+). M -  0 micro 5.9 
Cr(a+) ,  M +  + + +  18.0 Complement present 
Complement present 
0.7 0 micro Cr(a + ), M - 
No complement 
present 
Cr(a + I, M + + + +  5.9 
No complement 
mesent 
Cr(a+). M +  0 +(weak) 11.0 
Serum DTT-treated 
*Normal levels are 0-3% 
Table 2 gives the results of the sup(51)chromium RBC snr- 
viva1 study using Cr(a +), M - RBCs. Serologic studies 
were performed on a sample drawn four months post- 
transfusion. Anti-Cr sup(a) was not demonstrable at that 
time. Red cell survival of 91.8 percent at 10 minutes 
and 87.2 percent at 60 minutes suggested that immedi- 
ate destruction of transfused Cr(a+) RBCs would be 
unlikely However, long-term survival of the donor's 
cells was diminished with only 60.1 percent recovery 
at six days (T 1/2 = 12 days) and 10.8 percent at 14 
days (T 1/2 = 4.5 days). 
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Table 2 
Survival of sup(51)chromium-labeled Cr(a+),M-,E-,K-.S-, 
F y ( a - b - )  donorcells 
Red cell sup(51)Chromium 
Time recovery*% plasma activity'% T ½‡ (days) 
10 min 91.8 0.48 
60 min 87.2 0.21 
24 hr 79.9 
48 hr 74.7 
6 days 60.1 12 
14 days 10.8 4.5 
*Acceptable = > 70% recovery at 60 minutes. 
'Acceptable = < 5% sup(51)chromium plasma activity a t  10 and 
'Normal = 25-35 days. 
Results of serologic testing following the sup(51)chro- 
mium survival study are given in Table 3. No serum re- 
activity was observed until 14 days later when micro- 
scopic reactivity was noted in the IAT and DAT. An acid 
eluate prepared from the 14-day sample was micro- 
scopically positive with both Cr(a +), M - and Cr(a -), 
M +  RBCs. 
60 minutes. 
Table 3. 
Serum testing following the sup(51)chromium survival study 













"Titer 1 :4 with Cr(a + ). M -, E -, K- ,  S-, Fy(a - b -  ) donor 
'Acid eluate reactive with CR(a + ), M - and Cr(a - ), M + RBCs. 
cells. 
Discussion 
The patient's combination of anti-Cr sup(a) and other mul- 
tiple alloantibodies, including a possibly clinically sig- 
nificant anti-M, made it impossible to provide antigen- 
negative RBCs for transfusion. In addition, the patient's 
diagnosis of sickle cell anemia further complicated the 
evaluation of his response to transfusion therapy 
Reports of sup(51)chromium-labeled red cell survival 
studies using Cr(a+) red cells in individuals with 
antiCr sup(a) have shown varying results. Daniels5 reported 
significant destruction of Cr(a+) RBCs at 15 minutes, 
and McSwain and Robins" reported only 57.7 percent 
of the test dose surviving at 4 hours and 36.2 percent at 
21 hours. However, Smith et al. sup(7) found minimal imme- 
diate red cell destruction with 94 percent recovery at 
one hour and 82 percent at 17 hours, but long-term sur- 
vival was decreased, with only 34 percent of the 
labeled RBCs remaining after 21 days. Ross and Mc- 
Call' found similar results with 89 percent recovery at 
one hour, 82.6 percent at 24 hours, and 73 percent at 
96 hours. 
In 1980, the International Committee for Standardi- 
zation in Haematology sup(9) recommended that a one-hour 
red cell survival > 70 percent with < five percent 
sup(51)chromium label in the plasma in both the 10- and 
60-minute samples indicated that, in an emergency sit- 
uation, a unit volume of those cells could be transfused 
with little likelihood of immediate red cell destruc- 
tion. Silvergleid et al. sup(10) reported the use of the one- 
hour in vivo survival of sup(51)chromium-labeled RBCs to 
select units for transfusion in 38 patients for whom 
crossmatch-compatible blood was unavailable. His 
studies concluded that a one-hour survival of > 85 per- 
cent with a test dose of antigen-positive RBCs should 
not be associated with a hemolytic transfusion reac- 
tion. Davey et al. sup(11) suggested that 70 percent survival 
at 24 hours should be the standard for acceptable red 
cell survival. Thus, our patient's results of 87.2 percent 
survival at 60 minutes and 79.9 percent at 24 hours, 
and plasma values of 0.48 percent at 10 minutes and 
0.21 percent at 60 minutes suggest that immediate red 
cell destruction would be unlikely in this case. 
The initial slower rate of red cell removal was fol- 
lowed by accelerated red cell destruction during the 
first and second weeks, resulting in the survival curve 
exhibiting two slopes. The long-term survival of the 
donor red cells was decreased, with 60.1 percent and 
10.8 percent of the cells recovered after 6 and 14 days, 
respective& The T 1/2 of 12 days (normal 25-35 days), 
when calculated at 6 days, had decreased to 4.5 days 
during the second week of the study The hematocrit 
decreased concomitantly from 33 percent to 27 per- 
cent. A microscopically positive IAT and DAT were de- 
tected when the 14-day sample was tested. Testing of 
the eluate was limited due to the amount of specimen, 
but no specificity for Cr sup(a) was apparent, as both Cr(a -) 
and Cr(a+) cells were reactive. 
One explanation for the development of a positive 
IAT and DAT could be an anamnestic response of the 
anti-Cr sup(a) due to the test dose of Cr(a +) RBCs. However, 
our patient had experienced a similar decrease in he- 
matocrit following transfusion with Cr(a +), M -, E -, 
K -  , S - , Fy(a - b -) RBCs two months earlier with no 
increase in antibody reactivity on subsequent samples, 
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and the DAT remained negative. This was similar to 
our experience with other sickle cell patients trans- 
fused with phenotypically matched RBCs, who experi- 
enced apparent delayed hemolytic transfusion reac- 
tions several days posttransfusion. In these cases, no 
additional alloantibodies could be demonstrated even 
after exhaustive testing. 
Another explanation may be the possibility of auto- 
antibody formation in these patients. Petz et al. sup(12) have 
We are currently working with many blood centers 
to screen for Cr(a-), M- ,  E - ,  K - ,  S-, Fy(a-b-) 
blood for this patient in the event that his condition ne- 
cessitates transfusion in the future. 
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treatment may support this theory of autoantibody 
formation. 
Alloantibodies are not generally considered to be 
clinically significant unless they are active at 37°C or 
in the IAT: Anti-M was not demonstrable in saline at 
37°C or in the IAT on initial investigation thus, trans- 
fusion of M - red cells was not recommended. Subse- 
quent transfusions two weeks later elicited an anan- 
mestic response and anti-M w a s  then strongly reactive 
in all phases of testing, including 37°C and in the IAT 
Alperin et correlated sup(51)chromium red cell sur- 
vival studies with in vitro monocyte-macrophage 
phagocytosis, implicating anti-M in delayed hemolytic 
transfusion reactions. 
The MMA has been used as an alternative method to 
sup(51)cr- survival studies for predicting the clinical signifi- 
cance of alloantibodies. sup(l4) Our results indicated that 
Cr(a-), M +  red cells sensitized with the patient's 
serum were more reactive (18%) with the monocytes 
than the Cr(a+), M-  red cells (5.9%). As the normal 
range for this test is 0-3 percent, both the anti-Cr sup(a) and 
the anti-M appeared to be clinically significant. How- 
ever, the Cr(a-), M +  cells, sensitized with the pa- 
tient's serum, were more reactive with the monocytes. 
We considered this further support for the use of 
Cr(+), M - antigen-negative RBCs for transfusion of 
this patient because there were no Cr(a-), M -  
antigen-negative units of blood available. 
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